New Thai Government Reconsidering Patent Policy

Law360, New York (February 11, 2008, 12:00 AM EST) -- Thailand's new government is reportedly set to reconsider its aggressive stance on compulsory licenses for patented pharmaceuticals as it faces the threat of trade sanctions from the United States.

The review comes less than two months after the government of former Prime Minister Surayud Chulanont issued compulsory licenses in early January for Novartis' cancer drugs Glivec and Letrozole, Sanofi-Aventis’ breast and lung cancer drug Docetaxel, and Roche’s lung cancer drug Erlotinib.

In an 11th-hour deal, the military-installed government agreed earlier this month not to override the...
To view the full article, register now.